Ballentine Partners LLC Buys 810 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ballentine Partners LLC lifted its position in Edwards Lifesciences Co. (NYSE:EW) by 17.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,484 shares of the medical research company’s stock after purchasing an additional 810 shares during the period. Ballentine Partners LLC’s holdings in Edwards Lifesciences were worth $406,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the third quarter worth approximately $32,000. Avior Wealth Management LLC lifted its holdings in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the period. Peoples Bank KS bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group upped their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Piper Sandler decreased their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $78.48.

Insider Activity

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock worth $2,195,180 in the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $68.95 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a market capitalization of $40.66 billion, a P/E ratio of 9.95, a PEG ratio of 3.59 and a beta of 1.11. The stock has a 50-day simple moving average of $72.25 and a two-hundred day simple moving average of $70.86. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the business earned $0.59 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.